Essential role of TGF-β/Smad pathway on statin dependent vascular smooth muscle cell regulation

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Rodríguez Vita, Juan ^a   Sínchez Galín, Eva ^a   Santamaría, Beatriz ^a   Sánchez López, Elsa ^a   Rodrigues Díez, Raquel ^a   Blanco Colio, Luís Miguel ^a   Egido, Jesús ^a   Ortiz, Alberto ^a   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; RHO KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

MUS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; CELLS, CULTURED; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 58149112306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003959     Document Type: Article

References (42)

1. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556-1565.
2. Ehrenstein MR, Jury EC, Mauri C (2005) Statins for atherosclerosis-as good as it gets? N Engl J Med 352: 73-75.
3. Liao JK, Laufs U (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118.
4. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74: 196-206.
5. Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19: 1745-1754.
6. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, et al. (1995) Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest 96: 2667-2675.
7. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, et al. (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111: 2509-2517.
8. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
9. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, et al. (1999) Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 84: 1212-1222.
10. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V (2003) Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res 40: 37-46.
11. Grainger DJ (2007) TGF-beta and atherosclerosis in man. Cardiovasc Res 74: 213-222.
12. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, et al. (2001) Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89: 930-934.
13. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, et al. (2002) Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 22: 975-982.
14. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, et al. (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112: 1342-1350.
15. Porreca E, Di FC, Baccante G, Di NM, Cuccurullo F (2002) Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. J Am Coll Cardiol 39: 1752-1757.
16. Park HJ, Galper JB (1999) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci U S A 96: 11525-11530.
17. Chen CL, Liu IH, Fliesler SJ, Han X, Huang SS, et al. (2007) Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis. J Cell Sci 120: 3509-3521.
18. Chen CL, Huang SS, Huang JS (2008) Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors. J Cell Physiol 215: 223-233.
19. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, et al. (1998) 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490-500.
20. Guijarro C, Blanco-Colio LM, Massy ZA, O'Donnell MP, Kasiske BL, et al. (1999) Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int Suppl 71: S88-S91.
21. Erl W (2005) Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord 5: 135-144.
22. Leblanc V, Delumeau I, Tocque B (1999) Ras-GTPase activating protein inhibition specifically induces apoptosis of tumour cells. Oncogene 18: 4884-4889.
23. Morgan MA, Dolp O, Reuter CW (2001) Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97: 1823-1834.
24. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y (2004) Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 101: 7618-7623.
25. Sekine A, Fujiwara M, Narumiya S (1989) Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. J Biol Chem 264: 8602-8605.
26. Cicha I, Yilmaz A, Klein M, Raithel D, Brigstock DR, et al. (2005) Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler Thromb Vasc Biol 25: 1008-1013.
27. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EK, Medcalf RL, et al. (1990) Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A 87: 6939-6943.
28. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, et al. (2004) Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 35: 2253-2257.
29. Datta PK, Blake MC, Moses HL (2000) Regulation of plasminogen activator inhibitor- 1 expression by transforming growth factor-beta -induced physical and functional interactions between smads and Sp1. J Biol Chem 275: 40014-40019.
30. Leask A, Holmes A, Black CM, Abraham DJ (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278: 13008-13015.
31. McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, et al. (1999) The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 31: 1627-1642.
32. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, et al. (2008) Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 102: 68-76.
33. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2007) HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 50: 377-383.
34. Wang W, Huang XR, Canlas E, Oka K, Truong LD, D, et al. (2006) Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98: 1032-1039.
35. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R, Sanchez-Lopez E, Rupérez M, et al. (2008) Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int.
36. Boucher P, Li WP, Matz RL, Takayama Y, Auwerx J, et al. (2007) LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome. PLoS ONE 2: e448.
37. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata, et al. (2007) Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100: 1442-1451.
38. Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8: 1249-1256.
39. Clarke M, Bennett M (2006) Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis. Cell Cycle 5: 2329-2331.
40. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, et al. (2006) Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 12: 1075-1080.
41. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071-1080.
42. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, et al. (2000) Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 86: 1266-1272.